Medscape June 14, 2024
Amina Niasse

NEW YORK (Reuters) – About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year, according to a survey of global employers released on Thursday by the International Foundation of Employee Benefit Plans.

GLP-1 drugs for weight loss grew as a portion of employers’ overall medical claims spending to 8.9% in 2024 from 6.9% in 2023, the trade group’s survey found. Only about 26% of employers offered the drugs last year.

GLP-1 drugs promote weight loss by reducing appetite and causing the stomach to empty more slowly. First approved to treat diabetes, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are in high demand after having been shown...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Employer, Insurance, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
The Pandemic Proved That Remote Leadership Works
More than 65 Organizations Call on Workplaces to Provide Comprehensive Obesity Care Coverage
The state of AI: How organizations are rewiring to capture value
To reduce healthcare costs, address chronic conditions
Why Leaders Must Rethink Customer Experience Amid Continued AI Investment

Share This Article